Central nervous system metastasis in patients with HER2-positive metastatic breast cancer: Patient characteristics, treatment, and survival from systhers

Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Laura Chu, Haocheng Li, Vincent Antao, Melody Cobleigh

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Purpose: Patients with HER2-positive metastatic breast tor–negative disease, had higher risk of CNS metastasis. cancer (MBC) with central nervous system (CNS) metastasis Patients with CNS metastasis at diagnosis received first-line have a poor prognosis. We report treatments and outcomes in lapatinib more commonly (23.0% vs. 2.5%), and trastuzumab patients with HER2-positive MBC and CNS metastasis from less commonly (70.1% vs. 92.8%), than patients without CNS the Systemic Therapies for HER2-positive Metastatic Breast metastasis at diagnosis. Risk of death was higher with CNS Cancer Study (SystHERs). metastasis observed at or after diagnosis [median overall Experimental Design: SystHERs (NCT01615068) was a survival (OS) 30.2 and 38.3 months from MBC diagnosis, prospective, U.S.-based, observational registry of patients with respectively] versus no CNS metastasis [median OS not esti-newly diagnosed HER2-positive MBC. Study endpoints mable: HR 2.86; 95% confidence interval (CI), 2.05–4.00 and included treatment patterns, clinical outcomes, and patient-HR 1.94; 95% CI, 1.52–2.49]. Patients with versus without reported outcomes (PRO). CNS metastasis at diagnosis had lower quality of life at Results: Among 977 eligible patients enrolled (2012–enrollment. 2016), CNS metastasis was observed in 87 (8.9%) at initial Conclusions: Despite advances in HER2-targeted treatments, MBC diagnosis and 212 (21.7%) after diagnosis, and was not patients with CNS metastasis continue to have a poor prognosis observed in 678 (69.4%) patients. White and younger and impaired quality of life. Observation of CNS metastasis patients, and those with recurrent MBC and hormone recep-appears to influence HER2-targeted treatment choice.

Original languageEnglish (US)
Pages (from-to)2433-2441
Number of pages9
JournalClinical Cancer Research
Volume25
Issue number8
DOIs
StatePublished - Apr 15 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Central nervous system metastasis in patients with HER2-positive metastatic breast cancer: Patient characteristics, treatment, and survival from systhers'. Together they form a unique fingerprint.

  • Cite this

    Hurvitz, S. A., O'Shaughnessy, J., Mason, G., Yardley, D. A., Jahanzeb, M., Brufsky, A., Rugo, H. S., Swain, S. M., Kaufman, P. A., Tripathy, D., Chu, L., Li, H., Antao, V., & Cobleigh, M. (2019). Central nervous system metastasis in patients with HER2-positive metastatic breast cancer: Patient characteristics, treatment, and survival from systhers. Clinical Cancer Research, 25(8), 2433-2441. https://doi.org/10.1158/1078-0432.CCR-18-2366